The mental health clinical trials market is projected to grow from $3.52 billion in 2026 to $4.89 billion by 2030, with an 8.6% CAGR. Growth is fueled by increasing mental health disorder prevalence, adoption of digital and AI-driven interventions, decentralized trial models, and supportive regulations. Key players include Pfizer, Johnson & Johnson, and Merck. Asia-Pacific is expected to be the fastest-growing region, while North America remains the largest market. Challenges include tariffs raising costs, but these also encourage local sourcing and partnerships.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
